Cargando…

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism

Background: Hypoparathyroidism (HP) is caused by a deficiency in parathyroid hormone (PTH), which leads to hypocalcemia and hyperphosphatemia. Standard of care (SoC), i.e. large doses of calcium (Ca) and active vitamin D, worsens hypercalciuria and increases the serum Ca (sCa) x serum phosphate (sP)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Aliya Aziz, Rejnmark, Lars, Schwarz, Peter E, Vokes, Tamara J, Clarke, Bart Lyman, Rubin, Mishaela Ruth, Hofbauer, Lorenz C, Erikson, Erik, Palermo, Andrea, Pagotto, Uberto, Marcocci, Claudio, Ahmed, Intekhab, Mourya, Sanchita, Markova, Denka, Karpf, David B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208407/ http://dx.doi.org/10.1210/jendso/bvaa046.2209

Ejemplares similares

PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism
por: Khan, Aliya A, et al.
Publicado: (2021)

TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
por: Rubin, Mishaela R, et al.
Publicado: (2021)

OR21-1 The PaTH Forward Trial: Efficacy and Safety of TransCon PTH Through Week 84 for Adults With Hypoparathyroidism
por: Ahmed, Intekhab, et al.
Publicado: (2022)

A Randomized Double‐Blind Placebo‐Controlled First‐In‐Human Phase 1 Trial of TransCon PTH in Healthy Adults
por: Karpf, David B, et al.
Publicado: (2020)

Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial
por: Khan, Aliya A, et al.
Publicado: (2022)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Continuous rhPTH (1–34) treatment in chronic hypoparathyroidism
por: Fuss, Carmina Teresa, et al.
Publicado: (2020)

Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES)
por: Brod, Meryl, et al.
Publicado: (2021)

Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1–84)
por: Chen, Kristina S, et al.
Publicado: (2020)

Low health-related quality of life in hypoparathyroidism and need for PTH analog
por: Kontogeorgos, Georgios, et al.
Publicado: (2021)

Multicenter retro-prospective observational study on chronic hypoparathyroidism and rhPTH (1–84) treatment
por: Marcucci, G., et al.
Publicado: (2022)

Use of rhPTH(1-84) for hypoparathyroidism during early pregnancy and lactation
por: Liao, E Pauline, et al.
Publicado: (2023)

OR29-5 Phase 3 PaTHway Trial: Participants Treated With TransCon PTH Achieved Independence From Conventional Therapy While Maintaining Normal Serum Calcium
por: Khan, Aliya
Publicado: (2022)

Serum Calcium Levels in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Rejnmark, Lars, et al.
Publicado: (2021)

Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1–84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1–84) Compared With a Historical Control Cohort
por: Gosmanova, Elvira, et al.
Publicado: (2021)

Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study
por: Clarke, Bart L., et al.
Publicado: (2016)

Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
por: Ayodele, Olulade, et al.
Publicado: (2022)

SAT-396 A Non-Surgical Animal Model of Hypoparathyroidism for Testing PTH Analogues
por: Ramezani-Pour, Narjes, et al.
Publicado: (2020)

Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long‐Acting PTH Analog (LA‐PTH)
por: Noda, Hiroshi, et al.
Publicado: (2020)

OR07-03 Continuous Subcutaneous Delivery of RhPTH(1-84) by Pump in Adults with Hypoparathyroidism
por: Bove-Fenderson, Erin, et al.
Publicado: (2020)

Inverse correlation of intact PTH, oxidized PTH as well as non-oxidized PTH with 25-hydroxyvitamin D3 in kidney transplant recipients
por: Zuo, Jiao, et al.
Publicado: (2023)

Disruption of PTH Receptor 1 in T Cells Protects against PTH-Induced Bone Loss
por: Tawfeek, Hesham, et al.
Publicado: (2010)

The whole-PTH/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism
por: Tanaka, Motoko, et al.
Publicado: (2008)

OR07-01 Identification of the First Case of Acquired Autoimmune Parathyroid Hormone (PTH) Resistance Due to PTH1 Receptor (PTH1R) Autoantibodies
por: Mandl, Adel, et al.
Publicado: (2020)

Desperate Times Call for Desperate Measures: Use of Continuous Subcutaneous 1-34 PTH Infusion for Postsurgical Hypoparathyroidism
por: Haider, Adnan, et al.
Publicado: (2021)

Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range
por: Medas, Fabio, et al.
Publicado: (2019)

Disease Burden of Patients Living With Hypoparathyroidism: Results From the Voices of Hypopara Survey
por: Murphy, Deborah, et al.
Publicado: (2021)

Hypocalcemia after thyroidectomy: iPTH levels and iPTH decline are predictive? Retrospective cohort study()
por: Cannizzaro, Matteo Angelo, et al.
Publicado: (2018)

Case Report: Inactivating PTH/PTHrP Signaling Disorder Type 1 Presenting With PTH Resistance
por: Demaret, Tanguy, et al.
Publicado: (2022)

Correlation between iPTH Levels on the First Postoperative Day After Total Thyroidectomy and Permanent Hypoparathyroidism: Our Experience
por: Canu, Gian Luigi, et al.
Publicado: (2019)

Interaction between serum FGF-23 and PTH in renal phosphate excretion, a case-control study in hypoparathyroid patients
por: Saki, Forough, et al.
Publicado: (2020)

Subcutaneous Infusion of rhPTH(1-34) During Pregnancy and Nursing in a Woman With Autosomal Dominant Hypoparathyroidism 1
por: Shulman, Dorothy
Publicado: (2022)

Safety and Efficacy of PTH 1‐34 and 1‐84 Therapy in Chronic Hypoparathyroidism: A Meta‐Analysis of Prospective Trials
por: Puliani, Giulia, et al.
Publicado: (2022)

MON-LB092 Understanding the Patient-Centered Impact of Hypoparathyroidism on Functioning and Well-Being
por: Brod, Meryl, et al.
Publicado: (2019)

SAT-LB23 Paraneoplastic Hypercalcemia in a PTH Producing Adrenocortical Carcinoma - a Rare and Deadly Condition
por: Gruber, Sven, et al.
Publicado: (2020)

Endogenous PTH Deficiency Impairs Fracture Healing and Impedes the Fracture-Healing Efficacy of Exogenous PTH(1-34)
por: Ren, Yongxin, et al.
Publicado: (2011)

Decrease in the expression of the type 1 PTH/PTHrP receptor (PTH1R) on chondrocytes in animals with osteoarthritis
por: Becher, Christoph, et al.
Publicado: (2010)

Decreased expression of calcium-sensing receptor and parafibromin in secondary hyperparathyroidism with an abnormal whole PTH/intact PTH ratio
por: Yamada, Shunsuke, et al.
Publicado: (2013)

Acetate free citrate-containing dialysate increase intact-PTH and BAP levels in the patients with low intact-PTH
por: Kuragano, Takahiro, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t99vactiqnj9hum1r286askcng